AKTS
Aktis Oncology·NASDAQ
--
--(--)
--
--(--)
Latest data update time: Updated on 2026-03-29
Latest data update time: Updated on 2026-03-29
5.03 / 10Overall Score
NeturalInvestment Rating
5.03 / 10Overall Score
NeturalInvestment Rating
Is AKTS a Good Buy Right Now?
- Based on a composite score of 5.03/10, we rate AKTS as a Netural. Our analysis breaks down into 8.89/10 for Fundamentals, 3.36/10 for Technicals, and 3.94/10 for Sentiment, indicating the stock is likely to consolidate sideways.
Technical Analysis of AKTS?
Is AKTS undervalued or overvalued?
Is money flowing into or out of AKTS?
Is AKTS a Good Buy Right Now?
- Based on a composite score of 5.03/10, we rate AKTS as a Netural. Our analysis breaks down into 8.89/10 for Fundamentals, 3.36/10 for Technicals, and 3.94/10 for Sentiment, indicating the stock is likely to consolidate sideways.
Is AKTS undervalued or overvalued?
Technical Analysis of AKTS?
Is money flowing into or out of AKTS?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
